Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 31;20(1):2362449.
doi: 10.1080/21645515.2024.2362449. Epub 2024 Jun 26.

Integrative literature review on human papillomavirus vaccination recommendations in national immunization programs in select areas in the Asia-Pacific region

Wanatpreeya Phongsamart  1 , Pei-Jen Lou  2 , Isaya Sukarom  3 , Ying-Hui Wu  4 , Omer Zaidi  5 , Frieda Du  6 , Alyssa Simon  5 , Mark Bernauer  5
Affiliations
Review

Integrative literature review on human papillomavirus vaccination recommendations in national immunization programs in select areas in the Asia-Pacific region

Wanatpreeya Phongsamart et al. Hum Vaccin Immunother. .

Abstract

There is limited literature on current human papillomavirus (HPV) vaccination in the Asia-Pacific region. This integrative literature review was conducted to describe HPV vaccination programs in Hong Kong, Indonesia, Japan, South Korea, Malaysia, the Philippines, Singapore, Taiwan, Thailand, and Vietnam. Program descriptions, recommendations, f unding, and coverage data were extracted. Twenty-five citations were included. As of 2022, eight of the 10 areas of interest include HPV in their national immunization program (NIP) for school-aged girls; full implementation in Indonesia is expected in 2023 whereas Vietnam's NIP does not include HPV. Singapore also includes HPV vaccination for women (18-26 years). None of the HPV vaccination programs include males. In most areas (n = 7), programs include only one vaccine option. While female HPV NIPs are present in the Asia-Pacific region, opportunities remain to strengthen NIPs in broader populations (e.g., males, catch-up cohorts) to expand public health impact and provide gender equity in HPV vaccination.

Keywords: Asia; human papillomavirus; immunization; integrative review; papillomavirus vaccines.

PubMed Disclaimer

Conflict of interest statement

PJL: Received study f und ing from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. WP: Received study f und ing from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and from GSK. IS: Employee of MSD Thailand. YHW: Employee of MSD Taiwan. OZ, FD, AS, MB: Employees of OPEN Health.

Figures

Figure 1.
Figure 1.
PRISMA diagram.
See this image and copyright information in PMC

References

    1. Hebnes JB, Olesen TB, Duun-Henriksen AK, Munk C, Norrild B, Kjaer SK.. Prevalence of genital human papillomavirus among men in Europe: systematic review and meta-analysis. J Sex Med. 2014. Nov. 11(11):2630–6. doi:10.1111/jsm.12652. - DOI - PubMed
    1. Newman P, Lacombe-Duncan A. Human papillomavirus vaccination for men: advancing policy and practice. Future Virol. 2014;9(12):1033–47. doi:10.2217/fvl.14.91. - DOI
    1. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006. Aug 31;24(Suppl 3):S3/11–25. doi:10.1016/j.vaccine.2006.05.111. - DOI - PubMed
    1. de Sanjosé S, Serrano B, Tous S, de Sanjosé S, Alejo M, Lloveras B, Quirós B, Clavero O, Vidal A, Ferrándiz-Pulido C, et al. Burden of human papillomavirus (HPV)-related cancers attributable to HPVs 6/11/16/18/31/33/45/52 and 58. JNCI Cancer Spectr. 2018;2(4). doi:10.1093/jncics/pky045. - DOI - PMC - PubMed
    1. Mo Y, Ma J, Zhang H, Shen J, Chen J, Hong J, Xu Y, Qian C. Prophylactic and therapeutic HPV vaccines: current scenario and perspectives. Front Cell Infect Microbiol. 2022;12:12. 2022-July-04. doi:10.3389/fcimb.2022.909223. - DOI - PMC - PubMed

Publication types

Substances